Evidence map›Paper›PMID 41398327›Full record

ArticleScientific reports2025

Silent cerebral microvascular disease and the longitudinal risk of cognitive decline in atrial fibrillation.

Yusuke Kondo, Keitaro Senoo, Miyo Nakano, Yuki Shiko, Yohei Kawasaki, Masahiro Nakano, Takatsugu Kajiyama, Raita Uchiyma, Masato Yamanouchi, Satoru Kobayashi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yusuke KondoDepartment of Cardiovascular Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8670, Japan. simokita9933@msn.com.
Keitaro SenooDepartment of Cardiac Arrhythmia Research and Innovation, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Miyo NakanoDepartment of Advanced Cardiorhythm Therapeutics, Chiba University Graduate School of Medicine, Chiba, Japan.
Yuki ShikoDepartment of Biostatistics, Graduate School of Medicine, Saitama Medical University, Saitama, Japan.
Yohei KawasakiDepartment of Biostatistics, Graduate School of Medicine, Saitama Medical University, Saitama, Japan.
Masahiro NakanoDepartment of Advanced Cardiorhythm Therapeutics, Chiba University Graduate School of Medicine, Chiba, Japan.
Takatsugu KajiyamaDepartment of Advanced Arrhythmia Bioengineering, Chiba University Graduate School of Medicine, Chiba, Japan.
Raita UchiymaDepartment of Cardiology, Japan Community Healthcare Organization Chiba Hospital, Chiba, Japan.
Masato YamanouchiDepartment of Cardiology, Chiba Rosai Hospital, Ichihara, Japan.
Satoru KobayashiDepartment of Cardiology, Chibaken Saiseikai Narashino Hospital, Narashino, Japan.
Yoko PearcePearce Clinic, Chiba, Japan.
Toshihiro SaitoDepartment of Cardiology, Kashiwado Hospital, Chiba, Japan.
Ryo TakemuraClinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
Kusano KengoDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
Takashi KuritaDivision of Cardiology, Department of Internal Medicine, Kindai University School of Medicine, Osakasayama, Japan.
Takashi UnoDepartment of Radiology, Chiba University Graduate School of Medicine, Chiba, Japan.
Yoshio KobayashiDepartment of Cardiovascular Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8670, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SKAF study aimed to investigate the incidence of asymptomatic cerebrovascular disorders and cognitive decline in patients with nonvalvular atrial fibrillation (NVAF). We enrolled patients with NVAF aged ≥ 60 years and those with sinus rhythm (SR) for comparison. We collected the head magnetic resonance imaging test and Montreal Cognitive Assessment (MoCA) data at baseline and 24 months follow-up. The primary endpoint was the composite of silent ischemic stroke and microbleeding, and the secondary endpoint was cognitive decline, both over the 24 months of follow-up. In total, 313 patients were enrolled. The SR and NVAF groups comprised 99 and 213 patients, respectively (male, 193 [62%]; age, 72.2 ± 6.5 years). The composite of silent ischemic stroke and microbleeding showed no significant difference between the two groups (17.4% vs. 17.4%; p = 1.00). However, the NVAF group exhibited a significantly larger decline in cognition changes in MoCA score than the SR group (- 1.04 vs. 0,000; p = 0.041). The risk of silent cerebral microvascular disease was equivalent between patients with SR and NVAF. Clinically, NVAF affected cognitive decline.

Indexed as

Atrial FibrillationCerebrovascular DisordersCognitive DysfunctionAgedAged, 80 and overFemaleHumansIncidenceLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedRisk FactorsAtrial fibrillationCognitive declineEdoxabanMicrobleedingSilent stroke

Identifiers

PMID41398327
PMCPMC12708626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.